News Website

EU committee warns of women’s health ‘blind spot’ - FemTech World

EU committee warns of women’s health ‘blind spot’ FemTech World

Published: June 24, 2026, 2:04 p.m.

Read Full Article

Absci surges on Eli Lilly, private equity investments - MSN

Absci surges on Eli Lilly, private equity investments MSN

Published: June 24, 2026, 1:59 p.m.

Read Full Article

Baylen Out Loud: Baylen Gets Emotional Amidst Baby Making Talks - Fears She Cannot Have Kids! - TV Season & Spoilers -

Baylen Out Loud: Baylen Gets Emotional Amidst Baby Making Talks - Fears She Cannot Have Kids! TV Season & Spoilers -

Published: June 24, 2026, 1:53 p.m.

Read Full Article

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Benzinga

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program Benzinga

Published: June 24, 2026, 1:09 p.m.

Read Full Article

WHO Guidelines: What You Must Know About the Endometriosis Crisis - streamlinefeed.co.ke

WHO Guidelines: What You Must Know About the Endometriosis Crisis streamlinefeed.co.ke

Published: June 24, 2026, 11:46 a.m.

Read Full Article

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com

Published: June 24, 2026, 11:25 a.m.

Read Full Article

Absci stock surges 24% on positive Phase 1 hair loss drug data - Investing.com South Africa

Absci stock surges 24% on positive Phase 1 hair loss drug data Investing.com South Africa

Published: June 24, 2026, 11:14 a.m.

Read Full Article

Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com - Investing.com India

Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com Investing.com India

Published: June 24, 2026, 11:13 a.m.

Read Full Article

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times

Published: June 24, 2026, 10:48 a.m.

Read Full Article

Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart - Minichart

Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart Minichart

Published: June 24, 2026, 10:45 a.m.

Read Full Article

Latest Articles

EU committee warns of women’s health ‘blind spot’ - FemTech World

Absci surges on Eli Lilly, private equity investments - MSN

Baylen Out Loud: Baylen Gets Emotional Amidst Baby Making Talks - Fears She Cannot Have Kids! - TV Season & Spoilers -

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Benzinga

WHO Guidelines: What You Must Know About the Endometriosis Crisis - streamlinefeed.co.ke

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com

Absci stock surges 24% on positive Phase 1 hair loss drug data - Investing.com South Africa

Absci stock surges 24% on positive Phase 1 hair loss drug data By Investing.com - Investing.com India

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times

Absci Reports Positive Phase 1 Results for ABS-201, a First-in-Class PRLR Antibody for Hair Regrowth and Endometriosis – Minichart - Minichart

Subscribe to Our Newsletter